Complete remission seven years after treatment for metastatic malignant melanoma

Cancer

Volumn 77, Issue 5, 1996, Pages 900-902

  Petit, Thierry ^a,e   Borel, Christian ^a   Rixe, Olivier ^a   Avril, Marie Francoise ^b   Monnier, Alain ^c   Giroux, Bruno ^d   Weil, Marise ^a   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Service de Pneumologie   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^e CENTRE PAUL STRAUSS   (France)

Author keywords

fotemustine; long term survival; metastatic malignant melanoma; residual disease; surgery

Indexed keywords

FOTEMUSTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS POTENTIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; REMISSION INDUCTION; SPLENIC NEOPLASMS;

EID: 0030049724     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960301)77:5<900::AID-CNCR14>3.0.CO;2-7     Document Type: Article

References (16)

1. Legha S. Current therapy for malignant melanoma. Semin Oncol 1989:16:34-44.
2. Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF, Schaid DJ. Complete responses and long term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989:63:224-7.
3. Mc Govern VJ. Spontaneous regression of melanoma. Pathology 1975; 7:91-9.
4. Hill GJ II, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Late results after complete response to chemotherapy. Cancer 1984:53:1299-306.
5. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril M-F, et al. Final report of the French multicenter Phase II study of the Nitrosourea Fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990:66:1873-8.
6. Meulemans A, Giroux B, Hannoun P, Henzel D, Bizzari JP, Mohler J. Permeability of the two nitrosoureas, carmustine and fotemustine, in rat cortex. Chemotherapy 1989; 35:313-9.
7. Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 1994:5:249-51.
8. Samuel LM, Harvey VJ, Mitchell PL, Thompson PI, Mak D, Melville P, et al. Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. Eur J Cancer 1994;30A:2054-6.
9. Berd D, Mastrangelo MJ. Combination chemotherapy of metastatic melanoma. J Clin Oncol 1995; 13:796.
10. Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Somlo G, et al: Phase II trial of cisplatine and α-interferon in advanced malignant melanoma. J Clin Oncol 1992; 10:1574-8.
11. Kokoschka EM, Klocker J, Loicht U, Rehberger A, Macheiner W, Micksche M. Interferon-α-carboplatin combination therapy for metastatic melanoma: Phase II study. Eur J Cancer 1994;30A:2182.
12. Legha S, Ring S, Eton O, Plager C, Buzaid A, Papadopoulos N. Durable complete responses in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + dacarbazine (CVD) and IL2+α-interferon. Proc Am Soc Clin Oncol 1995; 14:1305.
13. Feun LG, Gutterman J, Burgess MA, Hersh EM, Mavligit G, Mc Bride CM, et al. The natural history of resectable metastatic melanoma (Stage IVA melanoma). Cancer 1982; 50:1656-63.
14. Keilholz U, Scheibenbogen C, Stoelben E, Saeger HD, Hunstein W. Immunotherapy of metastatic melenoma with Interferon α and Interleukine 2: pattern of progression in responders and patients with stable disease, with or without resection of residual disease. Eur J Cancer 1994;30A:955-8.
15. Henderson-Bakas M, Davis C, Poo WJ. Prolonged survival in patients with advanced melanoma after chemotherapy and resection. Proc Am Soc Clin Oncol 1994:13:397.
16. Frank SJ, Reilmann R, Applewhite J, Houghton AN, Meyers ML. Predictors of long-term survival in Stage IV melanoma. Proc Am Soc Clin Oncol 1995; 14:411.